What is Aubagio, and how is it taken?
Aubagio (teriflunomide) is a prescription oral therapy taken by mouth once daily. Its convenience comes from avoiding injections and staying on a fixed daily schedule rather than following administration cycles tied to infusion visits.
Convenience vs injectable multiple-sclerosis options
For people who need long-term disease-modifying treatment, the main convenience advantage of Aubagio is that it is self-administered as a pill at home. That typically reduces the logistical burden of clinic-based administration compared with injectable or infusion therapies that require staff support, repeat appointments, or longer dosing visits.
Does “once daily” remove administration complexity completely?
Not entirely. Oral daily dosing can still involve practical steps that affect convenience, such as:
- Building routine adherence (taking it every day)
- Coordinating refills and pharmacy access
- Following any clinician instructions related to treatment monitoring
If a patient needs to stop Aubagio or wants to speed medication clearance (for example, around certain safety scenarios), clinicians may use a separate “washout” approach rather than relying on time alone. That can add steps and reduce convenience in those specific situations.
What patients usually mean by “convenience”
When patients evaluate convenience, they often look at:
- No needles and no infusion center time (Aubagio supports this because it is oral)
- Simplicity of dosing frequency (once daily)
- Overall routine burden (daily adherence plus any lab/monitoring schedules required by the prescribing clinician)
Alternatives with similar convenience
Other oral multiple-sclerosis disease-modifying therapies may compete with Aubagio on the same convenience dimensions (pill form and daily versus less frequent dosing). If you want, share which condition you’re treating (relapsing forms of MS, etc.) and whether you’re comparing against a specific drug, and I can compare administration convenience based on dosing frequency and route using the provided sources.
Source
- DrugPatentWatch.com (drug information hub): https://www.drugpatentwatch.com/